A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

por Boven, E, Massard, C, Armand, J P, Tillier, C, Hartog, V, Brega, N M, Countouriotis, A M, Ruiz-Garcia, A, Soria, J C
Publicado 2010

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

por van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Publicado 2008